



DOCKET NO. AR02817USACON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: William W. VAN OSDOL et al.

Serial No.: 10/675,715

Art Unit: 1616

Filed : September 29, 2003

Examiner: Konata M. GEORGE

For : NOVEL FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF
FENOLDOPAM

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Dear Sir:

Your Petitioner, Alza Corporation, a corporation of the State of Delaware, having a registered office at Mountain View, CA 94043, represents that it is the Assignee of the entire right, title and interest in and to the subject matter disclosed in the above-captioned patent application by virtue of its being an offspring continuation of U.S. Patent Application Serial No. 09/361,026, filed July 23, 1999, now issued as U.S. Patent 6,699,497. Alza Corporation is the owner of U.S. Patent 6,699,497, as evidenced by the assignment recorded on October 29, 1998, at Reel 9562 / Frame 0988 in the United States Patent and Trademark Office. Above captioned U.S. Patent Application Serial No. 10/675,715, filed September 29, 2003 is a continuation of U.S. Patent Application Serial No. 09/361,026 filed July 23, 1999 (now issued as U.S. Patent 6,699,497), which claimed priority to Provisional Application Serial No. 60/094,059 filed July 24, 1998.


Your Petitioner, Alza Corporation hereby disclaims, under the provisions of 35 USC 253 and 37 CFR 1.321 and 3.73, the terminal part of

any patent granted on application Serial No. 10/675,715 which would extend beyond the expiration date of United States Patent No. 6,699,497 and hereby agrees that any patent so granted on application Serial No. 10/675,715 shall be enforceable only for and during such period that the legal title of said patent shall be the same as the legal title to United States Patent No. 6,699,497, this agreement to run with any patent granted on application Serial No. 10/675,715 and to be binding upon the grantee, its successors or assigns.

The Terminal Disclaimer fee of \$130.00 and any additional fees which may be owed in connection with the filing of this Terminal Disclaimer can be charged to Johnson & Johnson Deposit Account No. 10-0750. Three copies of this sheet are enclosed.

Signed at Mountain View, California, this 21st day of April, 2005.

Respectfully submitted,



Philip S. Yip
Registration No. 37,265
Attorney for Applicant

ALZA Corporation
c/o Johnson & Johnson
One Johnson & Johnson Plaza, WH 3221
New Brunswick, NJ 08933
Phone: 650-564-7054
Fax: 650-564-2195



DOCKET NO. AR02817USACON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: William W. VAN OSDOL et al.

Serial No.: 10/675,715

Art Unit: 1616

Filed : September 29, 2003

Examiner: Konata M. GEORGE

For : NOVEL FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF
FENOLDOPAM

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Dear Sir:

Your Petitioner, Alza Corporation, a corporation of the State of Delaware, having a registered office at Mountain View, CA 94043, represents that it is the Assignee of the entire right, title and interest in and to the subject matter disclosed in the above-captioned patent application by virtue of its being an offspring continuation of U.S. Patent Application Serial No. 09/361,026, filed July 23, 1999, now issued as U.S. Patent 6,699,497. Alza Corporation is the owner of U.S. Patent 6,699,497, as evidenced by the assignment recorded on October 29, 1998, at Reel 9562 / Frame 0988 in the United States Patent and Trademark Office. Above captioned U.S. Patent Application Serial No. 10/675,715, filed September 29, 2003 is a continuation of U.S. Patent Application Serial No. 09/361,026 filed July 23, 1999 (now issued as U.S. Patent 6,699,497), which claimed priority to Provisional Application Serial No. 60/094,059 filed July 24, 1998.


Your Petitioner, Alza Corporation hereby disclaims, under the provisions of 35 USC 253 and 37 CFR 1.321 and 3.73, the terminal part of

any patent granted on application Serial No. 10/675,715 which would extend beyond the expiration date of United States Patent No. 6,699,497 and hereby agrees that any patent so granted on application Serial No. 10/675,715 shall be enforceable only for and during such period that the legal title of said patent shall be the same as the legal title to United States Patent No. 6,699,497, this agreement to run with any patent granted on application Serial No. 10/675,715 and to be binding upon the grantee, its successors or assigns.

The Terminal Disclaimer fee of \$130.00 and any additional fees which may be owed in connection with the filing of this Terminal Disclaimer can be charged to Johnson & Johnson Deposit Account No. 10-0750. Three copies of this sheet are enclosed.

Signed at Mountain View, California, this 21st day of April, 2005.

Respectfully submitted,



Philip S. Yip
Registration No. 37,265
Attorney for Applicant

ALZA Corporation
c/o Johnson & Johnson
One Johnson & Johnson Plaza, WH 3221
New Brunswick, NJ 08933
Phone: 650-564-7054
Fax: 650-564-2195